We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Alpha Tau Medical Ltd | NASDAQ:DRTS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.07 | -2.26% | 3.03 | 3.03 | 3.06 | 3.0999 | 3.03 | 3.08 | 61,315 | 18:13:23 |
Event: | Citi 2024 Global Healthcare Conference |
Format: | 1-on-1 Meetings |
Date: | December 3, 2024 |
Time: | 8:30AM – 4:30PM EST |
Location: | Miami, FL |
Event: | Piper Sandler 36thAnnual Healthcare Conference |
Format: | Fireside Chat and 1-on-1 Meetings |
Date: | December 5, 2024 |
Time: | 10:00-10:25AM EST |
Location: | New York, NY |
Please reach out to your Citi and Piper Sandler representatives to schedule 1-on-1 meetings with Mr. Levy.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Investor Relations Contact: IR@alphatau.com
1 Year Alpha Tau Medical Chart |
1 Month Alpha Tau Medical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions